ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

28-Aug-2019

Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.

15-Aug-2019

Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.